Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024First Quarter 2024 • Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239) • Haematology revenue increased 46 per cent at CER to SEK 4,075 M (2,815), reflecting growth in all medicines, mainly driven by strong sales of Doptelet® of SEK 756 M (475), sales of Vonjo® of SEK 320 M (—), and sales of Aspaveli®/Empaveli® of SEK 240 M (95) • Immunology revenue decreased 11 per cent at CER to SEK 1,908 M (2,151),